Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis

Blood

Volumn 90, Issue 11, 1997, Pages 4283-4296

  Martins, Luis M ^b   Mesner, Peter W ^b   Kottke, Timothy J ^b   Basi, Guriqbal S ^b   Sinha, Sukanto ^b   Tung, Jay S ^b   Svingen, Phyllis A ^b   Madden, Benjamin J ^b   Takahashi, Atsushi ^b   McCormick, Daniel J ^b   Earnshaw, William C ^b   Kaufmann, Scott H ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C; DNA FRAGMENT; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL STRAIN HL 60; CELL STRAIN K 562; CELLULAR DISTRIBUTION; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; DNA FLANKING REGION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0030701895     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.11.4283.4283_4283_4296     Document Type: Article

References (69)

1. Dive C, Evans CA, Whetton AD: Induction of apoptosis - New targets for cancer chemotherapy. Semin Cancer Biol 3:417, 1992
2. Sachs L, Lotem J: Control of programmed cell death in normal and leukemic cells: New implications for therapy. Blood 82:15, 1993
3. Kerr JF, Winterford CM, Harmon BV: Apoptosis. Its significance in cancer and cancer therapy. Cancer 73:2013, 1994
4. Kaufmann SH: Proteolytic cleavage during chemotherapy-induced apoptosis. Mol Med Today 2:269, 1996
5. Hannun YA: Apoptosis and the dilemma of cancer chemotherapy. Blood 89:1845, 1997
6. Wyllie AH, Kerr JFR, Currie AR: Cell Death: The significance of apoptosis. Int Rev Cytol 68:251, 1980
7. Kyprianou N, English HF, Davidson NE, Isaacs JT: Programmed cell death during regression of the MCF7 human breast cancer following estrogen ablation. Cancer Res 51:162, 1991
8. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 Status and the efficacy of cancer therapy in vivo. Science 266:807, 1994
9. Martin DS, Stolfi RL, Colofiore JR, Nord LD, Sternberg S: Biochemical modulation of tumor cell energy in vivo: II. A lower dose of adriamycin is required and a greater antitumor activity is induced when cellular energy is depressed. Cancer Invest 12:296, 1994
10. Li X, Gong J, Feldman E, Seiter K, Traganos F, Darzynkiewicz Z: Apoptotic cell death during treatment of leukemias. Leuk Lymph 13:65, 1994
11. Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line, Blood 81:151, 1993
12. Green DR, Bissonnette RP, Cotter TG: Apoptosis and cancer. Import Adv Oncol 1994:37, 1994
13. Bedi A, Barber JP, Bedi GC, el-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J, Jones RJ: BCR-ABL-medicated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 86:1148, 1995
14. Hickman JA: Apoptosis and chemotherapy resistance. Eur J Cancer 32A:921, 1996
15. Wu GS, El-Deiry WS: Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or Bcl-2. Clin Cancer Res 2:623, 1996
16. Alnemri ES, Livingston DJ, Nicholson DW, Salveson G, Thornberry NA, Wong WW, Yuan J: Human ICE/CED-3 protease nomenclature. Cell 87:171, 1996
17. Martin SJ, Green DR: Protease activation during apoptosis: Death by a thousand cuts? Cell 82:349, 1995
18. Henkart PA: ICE Family proteases: Mediators of all apoptotic cell death? Immunity 4:195, 1996
19. Fraser A, Evan G: A license to kill. Cell 85:781, 1996
20. Takahashi A, Earnshaw WC: ICE-related proteases in apoptosis. Curr Opin Genet 6:50, 1996
21. Miller DK: The role of the caspase family of cysteine proteases in apoptosis. Semin Immunol 9:35, 1997
22. Thornberry NA, Rosen A, Nicholson DW: Control of apoptosis by proteases. Adv Pharmacol 41:155, 1997
23. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC: Cleavage of poly(ADP-ribose)polymerase by a proteinase with properties like ICE. Nature 371:346, 1994
24. Takahashi A, Alnemri ES, Lazebnik YA, Fernandes-Alnemri T, Litwack G, Moir RD, Goldman RD, Poirier GG, Kaufmann SH, Earnshaw WC: Cleavage of lamin A by Mch2α but not CPP32: Multiple ICE-related proteases with distinct substrate recognition properties are active in apoptosis. Proc Natl Acad Sci USA 93:8395, 1996
25. Nicholson DW: ICE/CED3-like proteases as therapeutic targets for the control of inappropriate apoptosis. Nature Biotech 14:297, 1996
26. Liu X, Zou H, Slaughter C, Wang X: DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 89:175, 1997
27. Miura M, Zhu H, Rotello R, Hartwieg EA, Yuan J: Induction of apoptosis in fibroblasts by IL-1 β-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell 75:653, 1993
28. Gagliardini V, Fernandez PA, Lee RK, Drexler HC, Rotello RJ, Fishman MC, Yuan J: Prevention of vertebrate neuronal death by the crmA Gene. Science 263:754, 1994
29. Chinnaiyan AM, Orth K, O'Rouke K, Duan H, Poirier GG, Dixit VM: Molecular ordering of the cell death pathway. J Biol Chem 271:4573, 1996
30. Livingston DJ: In vitro and in vivo studies of ICE inhibitors. J Cell Biochem 64:19, 1997
31. Kaufmann SH: Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: A cautionary note. Cancer Res 49:5870, 1989
32. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG: Specific proteolytic fragmentation of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis. Cancer Res 53:3976, 1993
33. Datta R, Banach D, Kojima H, Talanian RV, Alnemri ES, Wong WW, Kufe DW: Activation of the CPP32 protease in apoptosis induced by 1-β-D-arabinofuranosylcytosine and other DNA-damaging agents. Blood 88:1936, 1996
34. L inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res 56:4743, 1996
35. Liu X, Kim CN, Yang J, Jemmerson R, Wang X: Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome C. Cell 86:147, 1996
36. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng T-I, Jones DP, Wang X: Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science 275:1129, 1997
37. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD: The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science 275:1132, 1997
38. Martins LM, Kottke TJ, Mesner P, Basi GS, Sinha S, Frigon N Jr, Tatar E, Tung JS, Bryant K, Takahashi A, Svingen PA, Madden BJ, McCormick DJ, Earnshaw WC, Kaufmann SH: Activation of multiple interleukin-1β converting enzyme homologues in cytosol and nuclei of HL-60 human leukemia cell lines during etoposide-induced apoptosis. J Biol Chem 272:7421, 1997
39. Faleiro L, Kobayashi R, Fearnhead H, Lazebnik Y: Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells. EMBO J 16:2271, 1997
40. Takahashi A, Hirata H, Yonehara S, Imai Y, Lee K-K, Moyer RW, Turner PC, Mesner PW, Okazaki T, Sawai H, Kishi S, Yamamoto K, Okuma M, Sasada M: Affinity labeling displays the stepwise activation of ICE-related proteases by Fas, staurosporine, and CrmA-sensitive caspase-8. Oncogene 14:2741, 1997
41. Orth K, Chinnaiyan AM, Garg M, Froelich CJ, Dixit VM: The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. J Biol Chem 271:16443, 1996
42. Lozzio BB, Lozzio CB: Properties and usefulness of the original K562 human myelogenous leukemia cell line. Leuk Res 3:363, 1979
43. Chang MP, Bramhall J, Graves S, Bonavida B, Wisnieski BJ: Internucleosomal DNA cleavage precedes diphtheria toxin-induced cytolysis. Evidence that cell lysis is not a simple consequence of translation inhibition. J Biol Chem 264:15261, 1989
44. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG: Bcr-Abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83:1179, 1994
45. McGahon AJ, Nishioka WK, Martin SJ, Mahboubi A, Cotter TG, Green DR: Regulation of the Fas apoptotic cell death pathway by Abl. J Biol Chem 270:22625, 1995
46. Gangemi RM, Tiso M, Marchetti C, Severi AB, Fabbi M: Taxol cytotoxicity of human leukemia cell lines is a function of their susceptibility to programmed cell death. Cancer Chemother Pharmacol 36:385, 1995
47. Dubrez L, Goldwasser F, Genne P, Pommier Y, Solary E: The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia 9:1013, 1995
48. S induced differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-β-D-arabinofuranosylcytosine-mediated differentiation and apoptosis. Cell Growth Diff 7:1617, 1996
49. McGahon AJ, Brown DB, Martin SJ, Amarante-Mendes GP, Cotter TG, Cohen GM, Green DR: Downregulation of Bcr-Abl in K562 cells restores susceptibility to apoptosis: Characterization of the apoptotic death. Cell Growth Diff 4:95, 1997
50. Rowley PT, Keng PC, Kosciolek BA: The effect of bcr-abl antisense oligonucloetide on DNA synthesis and apoptosis in K562 chronic myeloid leukemia cells. Leuk Res 20:473, 1996
51. Adjei PN, Kaufmann SH, Leung WY, Mao F, Gores GJ: Selective induction of apoptosis in Hep 3B cells by topoisomerase I inhibitors: Evidence for a protease-dependent pathway that does not activate CPP32. J Clin Invest 98:2588, 1996
52. Covey JM, Jaxel C, Kohn KW, Pommier Y: Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res 49:5016, 1989
53. Lazebnik YA, Cole S, Cooke CA, Nelson WG, Earnshaw WC: Nuclear events of apoptosis in vitro in cell-free mitotic extracts: A model system for analysis of the active phase of apoptosis. J Cell Biol 123:7, 1993
54. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC: Measurement of protein using bicinchoninic acid. Anal Biochem 150:76, 1985
55. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual (ed 2). Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 1989
56. Kaufmann SH: Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51:1129, 1991
57. Pike BL, Robinson WA: Human bone marrow colony growth in agar-gel. J Cell Physiol 76:77, 1970
58. Martin SJ, Lennon SV, Bonham AM, Cotter TG: Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis. J Immunol 145:1859, 1990
59. Del Bino G, Darzynkiewicz Z: Camptothecin, teniposide, 4′-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induced degradation of nuclear DNA in the S phase of HL-60 cells. Cancer Res 51:1165, 1991
60. Prokocimer M, Shaklai M, Ben Bassat H, Wolf D, Goldfinger N, Rotter V: Expression of p53 in human leukemia and lymphoma. Blood 68:113, 1986
61. Köhl P, Köppler H, Schmidt L, Fritsch H-W, Holz J, Pflüger K-H, Jungclas H: Pharmacokinetics of high-dose etoposide after short-term infusion. Cancer Chemother Pharmacol 29:316, 1992
62. Mross K, Bewermeier P, Krüger W, Stockschläder M, Zander A, Hossfeld DK: Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies. J Clin Oncol 12:1468, 1994
63. Boldin MP, Goncharov TM, Goltsev YV, Wallach D: Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/ APO-1 and TNF receptor-induced cell death. Cell 85:803, 1996
64. Yin DX, Schimke RT: Bcl-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res 55:4922, 1995
65. Lock RB, Stribinskiene L: Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res 56:4006, 1996
66. Kyprianou N, King ED, Bradbury D, Rhee JG: Bcl-2 over expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 70:341, 1997
67. Potter MR, Moore M: Organ distribution of natural cytotoxicity in the rat. Clin Exp Immunol 34:78, 1978
68. Roger R, Issaad C, Pallardy M, Leglise MC, Turhan AG, Bertoglio J, Breard J: Bcr-abl does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells. Blood 87:1113, 1996
69. Froelich CJ, Orth K, Turbov J, Seth P, Gottlieb R, Babior B, Shah GM, Bleackley RC, Dixit VM, Hanna W: New paradigm for lymphocyte granule-mediated cytotoxicity. J Biol Chem 271:29073, 1996